Zaman Paula, Wang Julia, Blau Adam, Wang Weiping, Li Tina, Kohane Daniel S, Loscalzo Joseph, Zhang Ying-Yi
Department of Medicine, Brigham and Women's Hospital.
Department of Anesthesiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Int J Nanomedicine. 2016 Nov 18;11:6149-6159. doi: 10.2147/IJN.S119174. eCollection 2016.
Incorporation of proteins into dextran sulfate (DS)-chitosan (CS) nanoparticles (DSCS NPs) is commonly performed using entrapment procedures, in which protein molecules are mixed with DS and CS until particle formation occurs. As DS is an analog of heparin, the authors examined whether proteins could be directly incorporated into preformed DSCS NPs through a heparin binding domain-mediated interaction. The authors formulated negatively-charged DSCS NPs, and quantified the amount of charged DS in the outer shell of the particles. The authors then mixed the DSCS NPs with heparin-binding proteins (SDF-1α, VEGF, FGF-2, BMP-2, or lysozyme) to achieve incorporation. Data show that for DSCS NPs containing 100 nmol charged glucose sulfate units in DS, up to 1.5 nmol of monomeric or ~0.75 nmol of dimeric heparin-binding proteins were incorporated without significantly altering the size or zeta potential of the particles. Incorporation efficiencies of these proteins were 95%-100%. In contrast, serum albumin or serum globulin showed minimal incorporation (8% and 4%, respectively) in 50% physiological saline, despite their large adsorption in water (80% and 92%, respectively). The NP-incorporated SDF-1α and VEGF exhibited full activity and sustained thermal stability. An in vivo aerosolization study showed that NP-incorporated SDF-1α persisted in rat lungs for 72 h (34% remaining), while free SDF-1α was no longer detectable after 16 h. As many growth factors and cytokines contain heparin-binding sites/domains, incorporation into preformed DSCS NPs could facilitate in vivo applications of these proteins.
将蛋白质掺入硫酸葡聚糖(DS)-壳聚糖(CS)纳米颗粒(DSCS NPs)通常采用包封法,即将蛋白质分子与DS和CS混合,直至形成颗粒。由于DS是肝素的类似物,作者研究了蛋白质是否可以通过肝素结合域介导的相互作用直接掺入预先形成的DSCS NPs中。作者制备了带负电荷的DSCS NPs,并对颗粒外壳中带电荷的DS含量进行了定量。然后作者将DSCS NPs与肝素结合蛋白(SDF-1α、VEGF、FGF-2、BMP-2或溶菌酶)混合以实现掺入。数据表明,对于DS中含有100 nmol带电荷葡萄糖硫酸酯单元的DSCS NPs,最多可掺入约1.5 nmol单体或约0.75 nmol二聚体肝素结合蛋白,而不会显著改变颗粒的大小或zeta电位。这些蛋白质的掺入效率为95%-100%。相比之下,血清白蛋白或血清球蛋白在50%生理盐水中的掺入量极少(分别为8%和4%),尽管它们在水中的吸附量很大(分别为80%和92%)。掺入NP的SDF-1α和VEGF表现出完全活性和持续的热稳定性。一项体内雾化研究表明,掺入NP的SDF-1α在大鼠肺中持续存在72小时(约34%残留),而游离SDF-1α在16小时后不再可检测到。由于许多生长因子和细胞因子含有肝素结合位点/结构域,掺入预先形成的DSCS NPs中可以促进这些蛋白质的体内应用。